Julie H Ishida1,2, Reto Auer3,4, Eric Vittinghoff5, Mark J Pletcher6,5, Jared P Reis7, Stephen Sidney8, Kirsten L Johansen6,2,5, Kirsten Bibbins-Domingo6,5, Carmen A Peralta6,2,9, Michael G Shlipak6,9. 1. Departments of Medicine and julie.ishida@ucsf.edu. 2. Division of Nephrology, San Francisco Veterans Affairs Medical Center, San Francisco, California. 3. Institute of Primary Health Care, University of Bern, Bern, Switzerland. 4. Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland. 5. Epidemiology and Biostatistics, University of California, San Francisco, California. 6. Departments of Medicine and. 7. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 8. Division of Research, Kaiser Permanente, Oakland, California; and. 9. Kidney Health Research Collaborative, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, California.
Abstract
BACKGROUND AND OBJECTIVES: Marijuana use has become more widely accepted in the United States and has been legalized in many areas. Although it is biologically plausible that marijuana could affect kidney function, epidemiologic data are lacking. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a cohort study among young adults with preserved eGFR (i.e., eGFR≥60 ml/min per 1.73 m2) using data from the Coronary Artery Risk Development in Young Adults (CARDIA) study. At scheduled examinations occurring every 5 years and starting at study year 10 (calendar years, 1995-1996), cystatin C was collected over a 10-year period, and urine albumin-to-creatinine ratio was collected over a 15-year period. We investigated the cross-sectional association between current and cumulative marijuana use (in marijuana-years; one marijuana-year equals 365 days of marijuana use) and eGFR by cystatin C (eGFRcys) at year 10. In longitudinal analyses, we investigated the association between cumulative marijuana use and eGFRcys change and rapid (≥3%/year) eGFRcys decline over two 5-year intervals and prevalent albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g) over a 15-year period. RESULTS: Past or current marijuana use was reported by 83% (3131 of 3765) of the cohort, and the mean eGFRcys was 111 ml/min per 1.73 m2 at year 10. Over the following 10 years, 504 had rapid eGFRcys decline, and over the following 15 years, 426 had prevalent albuminuria. Compared with no use, daily current use and ≥5 marijuana-years of cumulative use were associated with lower eGFRcys at year 10: -4.5% (95% confidence interval, -8.1 to -0.7%; P=0.02) and -3.0% (95% confidence interval, -5.6 to -0.4%; P=0.03), respectively. Marijuana use was not significantly associated with eGFRcys change, rapid eGFRcys decline, or prevalent albuminuria. CONCLUSIONS: Although we identified a modest cross-sectional association between higher marijuana exposure and lower eGFRcys among young adults with preserved eGFR, our findings were largely null and did not demonstrate a longitudinal association between marijuana use and eGFRcys change, rapid eGFRcys decline, or prevalent albuminuria. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_08_24_CJASNPodcast_17_10.mp3.
BACKGROUND AND OBJECTIVES: Marijuana use has become more widely accepted in the United States and has been legalized in many areas. Although it is biologically plausible that marijuana could affect kidney function, epidemiologic data are lacking. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a cohort study among young adults with preserved eGFR (i.e., eGFR≥60 ml/min per 1.73 m2) using data from the Coronary Artery Risk Development in Young Adults (CARDIA) study. At scheduled examinations occurring every 5 years and starting at study year 10 (calendar years, 1995-1996), cystatin C was collected over a 10-year period, and urine albumin-to-creatinine ratio was collected over a 15-year period. We investigated the cross-sectional association between current and cumulative marijuana use (in marijuana-years; one marijuana-year equals 365 days of marijuana use) and eGFR by cystatin C (eGFRcys) at year 10. In longitudinal analyses, we investigated the association between cumulative marijuana use and eGFRcys change and rapid (≥3%/year) eGFRcys decline over two 5-year intervals and prevalent albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g) over a 15-year period. RESULTS: Past or current marijuana use was reported by 83% (3131 of 3765) of the cohort, and the mean eGFRcys was 111 ml/min per 1.73 m2 at year 10. Over the following 10 years, 504 had rapid eGFRcys decline, and over the following 15 years, 426 had prevalent albuminuria. Compared with no use, daily current use and ≥5 marijuana-years of cumulative use were associated with lower eGFRcys at year 10: -4.5% (95% confidence interval, -8.1 to -0.7%; P=0.02) and -3.0% (95% confidence interval, -5.6 to -0.4%; P=0.03), respectively. Marijuana use was not significantly associated with eGFRcys change, rapid eGFRcys decline, or prevalent albuminuria. CONCLUSIONS: Although we identified a modest cross-sectional association between higher marijuana exposure and lower eGFRcys among young adults with preserved eGFR, our findings were largely null and did not demonstrate a longitudinal association between marijuana use and eGFRcys change, rapid eGFRcys decline, or prevalent albuminuria. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_08_24_CJASNPodcast_17_10.mp3.
Authors: Kimber P Richter; Haroshena Kaur; Ken Resnicow; Niaman Nazir; Michael C Mosier; Jasjit S Ahluwalia Journal: Subst Abus Date: 2004-06 Impact factor: 3.716
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Kayte A Jenkin; Lannie O'Keefe; Anna C Simcocks; Esther Grinfeld; Michael L Mathai; Andrew J McAinch; Deanne H Hryciw Journal: J Endocrinol Date: 2015-03-24 Impact factor: 4.286
Authors: Reto Auer; Eric Vittinghoff; Kristine Yaffe; Arnaud Künzi; Stefan G Kertesz; Deborah A Levine; Emiliano Albanese; Rachel A Whitmer; David R Jacobs; Stephen Sidney; M Maria Glymour; Mark J Pletcher Journal: JAMA Intern Med Date: 2016-03 Impact factor: 44.409
Authors: Jared P Reis; Reto Auer; Michael P Bancks; David C Goff; Cora E Lewis; Mark J Pletcher; Jamal S Rana; James M Shikany; Stephen Sidney Journal: Am J Public Health Date: 2018-04 Impact factor: 9.308
Authors: Tarek Alhamad; Farrukh M Koraishy; Ngan N Lam; Sreelatha Katari; Abhijit S Naik; Mark A Schnitzler; Huiling Xiao; David A Axelrod; Vikas R Dharnidharka; Henry Randall; Rosemary Ouseph; Dorry L Segev; Daniel C Brennan; Radhika Devraj; Bertram L Kasiske; Krista L Lentine Journal: Transplantation Date: 2019-11 Impact factor: 4.939
Authors: Sang Gune K Yoo; Milan Seth; Muthiah Vaduganathan; Cyril Ruwende; Milind Karve; Ibrahim Shah; Thomas Hill; Hitinder S Gurm; Devraj Sukul Journal: JACC Cardiovasc Interv Date: 2021-08-23 Impact factor: 11.195
Authors: David Ruckle; Mohamed Keheila; Benjamin West; Pedro Baron; Rafael Villicana; Braden Mattison; Alex Thomas; Jerry Thomas; Michael De Vera; Arputharaj Kore; Philip Wai; D Duane Baldwin Journal: Clin Kidney J Date: 2018-11-15